王闽川

About

Over 16 years of investment experience in the health industry; an investment expert active in the international biomedical field. Co-founded Sanzheng Health (三正健康) in July 2016. From 2009 to 2016 worked in the Healthcare Industry Department of Hony Capital (弘毅投资), mainly responsible for investments in the biopharmaceutical and healthcare sectors. Major investments include: CSPC Pharmaceutical Group (1093.HK), InnoCare Pharma (9969.HK), Keymed Biosciences (2162.HK), Libang Pharmaceutical (礼邦医药), Haihe Biopharma (海和药物), EdiGene (博雅辑因), Dingtai Pharma Research (鼎泰药研), Xinkanghe (鑫康合), Anjisheng Biotech (安济盛生物) and others. Member of the Biotech Advisory Group of Hong Kong Exchanges and Clearing Limited (HKEX), review consultant for the Innovation and Technology Fund of the Hong Kong SAR Government, and Distinguished Research Fellow at the International Research Center for Medicine Management (Peking University). Bachelor's degree from Peking University Health Science Center; Master's in Pharmacology and PhD in Biomedicine from the University of Cambridge.

Source (opens in a new tab)